Patents by Inventor Wilma Thuer
Wilma Thuer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10316316Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.Type: GrantFiled: April 19, 2016Date of Patent: June 11, 2019Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: David L Lewis, David B Rozema, Darren H Wakefield, Torsten Hoffman, Erik Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
-
Publication number: 20170204408Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.Type: ApplicationFiled: April 19, 2016Publication date: July 20, 2017Inventors: David L Lewis, David B Rozema, Darren H Wakefield, Torsten Hoffman, Erik Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
-
Publication number: 20160222384Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.Type: ApplicationFiled: April 19, 2016Publication date: August 4, 2016Inventors: David L Lewis, David B Rozema, Darren H Wakefield, I, Torsten Hoffman, Erik Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
-
Patent number: 9011919Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.Type: GrantFiled: September 14, 2012Date of Patent: April 21, 2015Assignee: Arrowhead Madison Inc.Inventors: David B. Rozema, David L. Lewis, Darren H. Wakefield, Torsten Hoffmann, Eric Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
-
Patent number: 8853132Abstract: The trivalent phosphorous atom of a compound is reacted with a reagent in such a manner that a stable phosphate mimetic or a specifier is formed. Phosphoramidites with a phosphorous atom containing at least one hydroxyl residue which is provided with a protective group are reacted for this purpose with a free hydroxyl group: In the first synthesis cycle the hydroxyl group is linked to a solid support via a cleavable or non-cleavable linker. In further synthesis cycles the hydroxyl group is created by cleavage of the protective group from the growing oligomer. This results in formation of a phosphorous acid triester which is reacted with azides. By selecting suitable monomers for the synthesis which have a defined stereoconformation compounds of Formula 1 are produced in a stereocontrolled manner.Type: GrantFiled: September 13, 2013Date of Patent: October 7, 2014Assignee: Roche Diagnostics Operations, Inc.Inventors: Dieter Heindl, Dirk Kessler, Angelika Roesler, Christoph Seidel, Wilma Thuer
-
Publication number: 20140045719Abstract: The trivalent phosphorous atom of a compound is reacted with a reagent in such a manner that a stable phosphate mimetic or a specifier is formed. Phosphoramidites with a phosphorous atom containing at least one hydroxyl residue which is provided with a protective group are reacted for this purpose with a free hydroxyl group: In the first synthesis cycle the hydroxyl group is linked to a solid support via a cleavable or non-cleavable linker. In further synthesis cycles the hydroxyl group is created by cleavage of the protective group from the growing oligomer. This results in formation of a phosphorous acid triester which is reacted with azides. By selecting suitable monomers for the synthesis which have a defined stereoconformation compounds of Formula 1 are produced in a stereocontrolled manner.Type: ApplicationFiled: September 13, 2013Publication date: February 13, 2014Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.Inventors: Dieter Heindl, Dirk Kessler, Angelika Roesler, Christoph Seidel, Wilma Thuer
-
Patent number: 8569515Abstract: The trivalent phosphorous atom of a compound is reacted with a reagent in such a manner that a stable phosphate mimetic or a specifier is formed. Phosphoramidites with a phosphorous atom containing at least one hydroxyl residue which is provided with a protective group are reacted for this purpose with a free hydroxyl group: In the first synthesis cycle the hydroxyl group is linked to a solid support via a cleavable or non-cleavable linker. In further synthesis cycles the hydroxyl group is created by cleavage of the protective group from the growing oligomer. This results in formation of a phosphorous acid triester which is reacted with azides. By selecting suitable monomers for the synthesis which have a defined stereoconformation compounds of Formula 1 are produced in a stereocontrolled manner.Type: GrantFiled: May 3, 2011Date of Patent: October 29, 2013Assignee: Roche Diagnostics Operations, Inc.Inventors: Dieter Heindl, Dirk Kessler, Angelika Roesler, Christoph Seidel, Wilma Thuer
-
Publication number: 20130245091Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.Type: ApplicationFiled: September 14, 2012Publication date: September 19, 2013Applicant: ARROWHEAD MADISON INC.Inventors: David B. Rozema, David L. Lewis, Darren H. Wakefield, Torsten Hoffmann, Eric A. Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
-
Publication number: 20110212861Abstract: The trivalent phosphorous atom of a compound is reacted with a reagent in such a manner that a stable phosphate mimetic or a specifier is formed. Phosphoramidites with a phosphorous atom containing at least one hydroxyl residue which is provided with a protective group are reacted for this purpose with a free hydroxyl group: In the first synthesis cycle the hydroxyl group is linked to a solid support via a cleavable or non-cleavable linker. In further synthesis cycles the hydroxyl group is created by cleavage of the protective group from the growing oligomer. This results in formation of a phosphorous acid triester which is reacted with azides. By selecting suitable monomers for the synthesis which have a defined stereoconformation compounds of Formula 1 are produced in a stereocontrolled manner.Type: ApplicationFiled: May 3, 2011Publication date: September 1, 2011Inventors: Dieter Heindl, Dirk Kessler, Angelika Roesler, Christoph Seidel, Wilma Thuer
-
Publication number: 20110207799Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.Type: ApplicationFiled: February 22, 2011Publication date: August 25, 2011Applicant: ROCHE MADISON INC.Inventors: David B. Rozema, David L. Lewis, Darren H. Wakefield, Torsten Hoffmann, Erik Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis